Breast cancer study uses MR contrast agent
MR isn’t widely used for breast cancer diagnosis, but finding a contrast agent that images lesions and other suspicious growths easily may be the breakthrough clinicians need to begin using the platform to detect breast cancers.Hitachi Medical
MR isnt widely used for breast cancer diagnosis, but finding a contrast agent that images lesions and other suspicious growths easily may be the breakthrough clinicians need to begin using the platform to detect breast cancers.
Hitachi Medical Systems and Epix Medical studied the use of contrast agent AngioMARK employed with a low-field MR. Cambridge, MA-based Epix develops contrast agents designed to work with MR imaging.
AngioMARK and the studys findings will be discussed April 5 at the American Association for Cancer Researchs annual meeting in San Francisco.
AngioMARK-enhanced MRI provides high-quality images, which may be useful for very early detection of breast tumors, said Michael Webb, Epix Medicals CEO.
Webb noted that there are some advantages to using MR with a contrast agent to detect breast cancer. For example, using an open, low-field MR system to detect breast lesions early on in high-risk patients may be less expensive for the hospital and more comfortable for the patient than a closed high-field MR system.
The combination of AngioMARK and open MR scanners accurately detected small breast cancers not easily seen through traditional mammography because the contrast agent has a strong signal enhancement and prolonged imaging time, said Dr. Steven Edell, medical director of Delaware Open MRI and one of the studys principal investigators.
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
Could an Emerging PET Tracer be a Game Changer for Detecting Hepatocellular Carcinoma?
June 23rd 2025In addition to over 90 percent sensitivity in detecting hepatocellular carcinoma (HCC), the glypican-3 (GPC3) targeted PET tracer 68Ga-aGPC3-scFv appeared to be advantageous in identifying HCC tumors smaller than one centimeter, according to pilot study findings presented at the SNMMI conference.
SNMMI: What a New Meta-Analysis Reveals About Radiotracers for PET/CT Detection of PCa
June 22nd 2025While (68Ga)Ga-PSMA-11 offers a pooled sensitivity rate of 92 percent for prostate cancer, (18F)-based radiotracers may offer enhanced lesion detection as well as improved imaging flexibility, according to a meta-analysis presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.
